Medication therapy management for chronic disease patients with uncontrolled diabetes Nutritional, Metabolic, Endocrine
Conditions
Interventions
The study involves an intervention group comprising a community pharmacy-based medication therapy management (MTM) programme for a minimum of 6 months and a control group of standard care in community
Sponsors
Princess Nourah bint Abdulrahman University
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Uncontrolled diabetes (defined as having glycated haemoglobin blood (HbA1c) = 8%) 2. Age 18 years and over 3. Able to provide informed consent 4. Have a continuous active status with the medical center (defined as having a record of at least 1 visit in the 6 months before screening) 5. Speak either Arabic or English
Exclusion criteria
Exclusion criteria: 1. Severe mental illness or dementia or significant cognitive impairment 2. Gestational diabetes 3. Unstable acute complications/illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin A1C (HbA1C) levels measured using a blood test at baseline, 3 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical parameters measured using blood test at baseline, 3 and 6 months: 1.1. Blood pressure (BP) (mmHg) (systolic BP and diastolic BP) 1.2. Lipid profile (mg/dl) (low-density lipoprotein [LDL], total cholesterol [TC], triglyceride [TG]) 1.3. Albumin-to-creatinine ratio (ACR) (mg/g) and serum creatinine (sCr) (mg/dl) 2. Description of MTM programme measured using chi-square tests and reported as no. and % using Stata/SE 17 at baseline, 3 and 6 months: 2.1. Number of patient visits 2.2. Number and type of referrals 2.3. Pharmacist consultation time per participant (minutes) 3. Number and types of drug-related problems (DRPs): 3.1. DRPs that need an additional drug 3.2. Supply drugs without indication 3.3. Adverse drug reaction 3.4 Ineffective drug 3.5. High/low dose 3.6. Noncompliance 4. Health services utilization including the number and reasons for hospitalization or ED during the study period measured using the Firth-type logistic regression and reported as no. and % using Stata/SE 17 at baseline, 3 and 6 months 5. Patient medication adherence measured using the Medication Adherence Report Scale-5 (MARS-5) at baseline and 6 months 6. Diabetes distress measured using the Diabetes Distress Scale (DDS) at baseline and 6 months 7. Patient satisfaction with pharmacist services using The Patient Satisfaction with Pharmacist Services Questionnaire (PSPSQ 2. 0) at 6 months | — |
Countries
Saudi Arabia
Outcome results
None listed